Histone H3K36M mutation and trimethylation patterns in chondroblastoma Aims: Histones are essential components of chromatin, and mutations in histones lead to alterations in methylation and acetylation, which play an important role in tumorigenesis. Most of the chondroblastomas harbour the H3K36M mutation. With the availability of a mutation-specific antibody, we sought to assess the sensitivity of this antibody and the alterations of histone methylation in a series of chondroblastoma cases. Methods and results: Immunohistochemical staining with antibodies against H3K36M, trimethylated histones (H3K27me3 and H3K36me3) and an osteoblastic marker (SATB2) was performed on 27 chondroblastomas from 27 patients. The clinical and radiological characteristics of each patient were reviewed. All 27 tumours showed typical radiological and histological features of chondroblastoma, with a subset of cases showing secondary aneurysmal bone cyst changes (11/27 ), giant-cell-rich foci (4/27), and matrix-rich areas mimicking chondromyxoid fibroma (1/27). All except one case (26/27, 96%) showed positive H3K36M immunostaining (nuclear). In the majority of cases, there was a diffuse staining pattern. Immunohistochemical staining for H3K27me3 and H3K36me3 showed a heterogeneous staining pattern in all cases, regardless of mutation status. None of the cases showed loss of positivity or diffuse positivity.
Introduction
Histones are protein components of chromatin, and their major role is to package the DNA into nucleosomes and regulate gene expression. There are five major types of histones: one linker histone, H1, and four core histones, H2A, H2B, H3, and H4. Posttranslational modifications of histones, including methylation, acetylation, phosphorylation, ubiquitylation, and sumoylation, play an important role in the epigenetic regulation of gene expression, leading to either gene activation or gene repression. Among all histones, H3 and H4 are most commonly affected by modifications. Mutations and post-translational modifications of histones are involved in tumorigenesis, drug resistance, and prognosis. 1 Recent studies have identified mutations of H3 in giant-cell tumours of bone and chondroblastomas. 2 The majority of chondroblastomas harbour the H3K36M mutation in H3F3B and H3F3A, and most of the giant-cell tumours of bone contain the G34W mutation in H3F3A. 2 These mutations may represent dominant driver events in these tumours, and are rarely detected in other bone tumours. 2 Lu et al. further studied the underlying mechanism of the effect of H3K36M in tumorigenesis, and found that the H3K36M mutation impairs chondrocytic differentiation of mesenchymal progenitor cells. 3 Mesenchymal progenitor cells expressing H3K36M, when transplanted into immunodeficient mice, can form tumours resembling human undifferentiated sarcoma. 3 The authors also found that histone methylation is driven by H3F3B mutation. The H3K36M mutation leads to loss of H3K36me2/H3K36me3 and gain in H3K27me2/H3K27me3, 3 the latter functioning as a repressor of gene transcription.
In this study, we retrospectively reviewed 27 cases of chondroblastoma that were treated from 2000 to 2013 at our institution. The clinicopathological features of these tumours were reviewed, and immunohistochemical studies of mutant H3 (H3K36M) and methylated H3 (H3K36me3 and H3K27me3) were performed. The study was performed to confirm the presence of the H3K36M mutation by using a mutant-specific antibody in chondroblastomas, and to correlate mutation status with clinicopathological features and the expression of H3K27me3 and H3K36me3.
Materials and methods

P A T I E N T S E L E C T I O N A N D E V A L U A T I O N O F C L I N I C A L C H A R A C T E R I S T I C S
Patients who underwent surgical treatment during the period from 2000 to 2013 with a final pathological diagnosis of chondroblastoma were included in this study. Twenty-seven patients were identified. Medical records were reviewed for the patients' age, gender, site of involvement, radiological findings, treatment, follow-up, and recurrence of tumour. In selected cases, radiology input was obtained from a musculoskeletal radiologist. The project was approved by the Office of Clinical Research at Memorial Sloan Kettering Cancer Center (IRB-16-1490).
H I S T O L O G Y A N D I M M U N O H I S T O C H E M I S T R Y
The specimens were fixed in formalin and decalcified as needed. Routine haematoxylin and eosin sections were prepared and reviewed by three pathologists independently. Immunohistochemical staining with antibodies specific for H3K36M (RM193; Cayman Chemical, San Francisco, CA, USA; 1:2500), H3K27me3 (Cell Signaling Technology, Danvers, MA, USA; 1:200), H3K36me3 (MABI 0333; Active Motif, Carlsbad, CA, USA; 1:500) and the osteoblastic marker SATB2 (EP281; Cell Marque, Rocklin, CA, USA; 1:400) was performed on either the Leica platform (Leica Biosystems Inc., Buffalo Grove, IL, USA; H3K36M, H3K27me3, and H3K36me3) or the Benchmark Ultra platform (Roche Diagnostics USA, Indianapolis, IN, USA; SATB2). A known positive control was used for each antibody to ensure the quality of staining. Nuclear staining of H3K36M and SATB2 was interpreted as positive or negative regardless of the percentage of tumour cell staining. The staining pattern of H3K27me3 and H3K36me3 was semiquantitatively assessed with a method modified from the widely used H-score. 4 Briefly, the staining intensity of H3K27me3 or H3K36me3 was graded as follows: 0, negative; 1, weak; 2, intermediate; and 3, strong. The percentage of positive tumour cells in the tumour tissue was then estimated. The modified Hscore was calculated with the following equation: modified H-score = % of positive cells 9 staining intensity. Statistical analysis was performed to determine the correlation of H-scores between H3K27me3 and H3K36me3 staining.
Results
C L I N I C A L P R E S E N T A T I O N
The clinical features of the 27 cases are summarised in Table 1 . The 27 patients included 20 males and seven females, with ages ranging from 11 to 34 years (median, 19.5 years). Sixteen patients were in their second decade of life, eight were in their third decade, and three were in their fourth decade.
The locations of tumours included the femur (n = 7; three in the greater trochanter, and four in the distal epiphysis), humerus (n = 7; six in the proximal epiphysis, and one in the trochlea), ischium (n = 1), scapula (n = 3; two in the acromion, and one in the coracoid process), talus (n = 5), and tibia (n = 4; all in the proximal epiphysis). Twenty-five tumours were primaries and the other two were recurrences, the primaries of which were curetted at outside hospitals 8 and 18 months before surgery at our hospital. All tumours were treated by curettage with bone grafting or cementation. Selected cases were treated with preoperative embolisation or cryoablation during surgery. One patient was lost to follow-up immediately after surgery, and the other 26 patients were followed for 1-129 months after surgery (median, 30 months; mean, 40 AE 35 months). One tumour showed local recurrence at 23 months after primary surgery, and the recurrent tumour was curetted again; no recurrence was seen after a followup of another 103 months. One patient had lung metastases at 12 months after surgery, and was then lost to follow-up.
R A D I O L O G I C A L C H A R A C T E R I S T I C S
The available imaging studies, including plain radiographs, computed tomography (CT) and magnetic resonance imaging (MRI) were reviewed for all the cases. Except for the one tumour that involved the left ischium, all of the other 24 primary tumours were located in the epiphyseal or apophyseal bone and showed typical radiological findings, including lytic lesion, a well-circumscribed nature, sclerotic rimming, and prominent oedema (Figure 1 ). Among these 24 tumours, one tumour showed cortical breakthrough (trochlea of humerus); the tumour was curetted, and the patient remained free of disease at 16 months after surgery.
P A T H O L O G I C A L C H A R A C T E R I S T I C S
All 27 tumours showed the typical morphology of chondroblastoma, including sheets of polygonal cells with eosinophilic cytoplasm and nuclei with grooving and scattered osteoclast-type giant cells (Figure 1) . Primitive chondroid foci with chicken-wire calcification were frequently seen. Eleven tumours showed secondary aneurysmal bone cyst-like changes, four tumours showing giant-cell-rich foci mimicking giant-cell tumour, and one tumour showing matrix-rich areas mimicking chondromyxoid fibroma ( Figure 2 ).
I M M U N O H I S T O C H E M I S T R Y
Twenty-six of the 27 cases (96%) showed nuclear positivity for H3K36M antibody, and the staining pattern was overall diffuse in majority of cases ( Figure 1 ; Table 1 ). Whereas internal non-neoplastic tissue, i.e. endothelial cells and fibrous tissue, showed consistent strong staining, the tumour cells showed a Table 1 . heterogeneous pattern for both H3K27me3 and H3K36me3 immunostaining ( Figure 1 ; Table 1 ). The modified H-scores of H3K27me3 staining varied from 30 to 270 (median, 130), and the scores of H3K36me3 staining varied from 80 to 270 (median, 195) . Statistical analysis showed that the H-scores of H3K27me3 and H3K36me3 staining were positively correlated, and that the Pearson correlation coefficient was 0.65 (P < 0.001).
Only one tumour was negative for H3K36M antibody. The patient was a 22-year-old female, and the tumour was located in the greater trochanter of the right femur. The tumour showed typical radiological and pathological features of chondroblastoma, and negative staining for H3K27me3 and focal weak staining for H3K36me3. It is possible that fixation and decalcification may have contributed to the absence of staining in this case. The tumours with ABC-like, giant-cell-rich and matrixrich foci all showed diffuse positive immunostaining for H3K36M (Figure 2) . Immunostaining for SATB2, a marker of osteoblastic differentiation, was positive in the tumour cells in 21 of 26 tumours (81%; Figure 1 ), whereas 11 of them showed diffuse staining, and the rest showed focal staining (Table 1) . 
C H O N D R O B L A S T O M A W I T H L U N G M E T A S T A S I S
In this series, there was only one case of lung metastasis. The patient was a 13-year-old boy with a large left ischial lesion. The lesion had been curetted twice at an outside hospital before the patient came to our hospital. Plain radiographs and a CT scan showed a large expansile lytic lesion involving the left ischium. The lesion extended beyond the contour of the normal cortex, but appeared to be confined by a thin shell of bone ( Figure 3 ). On MRI, the lesion showed multicystic changes with fluidfluid levels ( Figure 3) . A chest radiograph was negative at the time of admission. The lesion was embolised, curetted, and treated with liquid nitrogen and allografting. Pathological examination demonstrated a chondroblastoma with typical morphology and secondary aneurysmal bone cyst-like changes. The tumour was positive for H3K36M antibody, supporting the diagnosis of chondroblastoma (Figure 3 ).
Three months later, evidence of local recurrence was again seen on MRI imaging, and a biopsy confirmed the recurrence of chondroblastoma (Figure 3 ). At 11 months after the primary surgery, a chest radiograph revealed multiple nodules in both lungs. Biopsy of one of the nodules in the left lower lobe showed the typical morphology of chondroblastoma. Tumour cells were positive for H3K36M antibody, similarly to the primary tumour. The patient decided to continue his treatment with his primary physician, and was lost to follow-up ( Figure 3 ).
Discussion
Chondroblastomas are most commonly seen in patients in their second decade of life. In a large series of 103 cases reported by Konishi et al., the ages ranged between 8 and 61 years. 5 Chondroblastomas in the first decade or in older adults are relatively rare. Dahlin et al. reported chondroblastomas in two 5-year-old children. 6 In a group of patients with chondroblastoma in the hands or feet, the youngest patient was aged 7 years, and the oldest was aged 52 years. 7 Chondroblastomas at unusual locations such as the ribs tend to affect older individuals. 6 The Figure 3 . A case of chondroblastoma with lung metastasis. The patient was a 13-year-old male. A, A preoperative radiograph showed a lytic ischial lesion(arrow). B,C, Serial computed tomography (CT) examinations over a period of 2 months showed increased size and cortical destruction of the tumour (arrows). The tumour was treated by embolisation, curettage, and bone grafting. D, Histologically, the tumour was composed of sheets of uniform cells with chondroid differentiation, aneurysmal bone cyst-like change, and frequent multinucleated giant cells. E,F, The tumour cells showed typical morphology of chondroblasts (E) and were strongly positive for H3K36M (F). G, Three months after curettage, the radiograph showed recurrent tumour (arrows). H,I, Magnetic resonance imaging T2-weighted (H) and T1-weighted (I) fat-saturated post-contrast images showed fluid levels (arrowheads) and enhancing components (arrow) in the tumour. J, The recurrence was biopsied, and tumour again showed positive H3K36M immunostaining. K, At 11 months after surgery, CT showed pulmonary nodules (arrows). L,M, Needle core biopsy of a lung nodule confirmed metastatic chondroblastoma, which showed similar morphology to that seen in the primary tumour (L), and tumour cells showed positive H3K36M immunostaining (M). [Colour figure can be viewed at wileyonlinelibrary.com] ages of our patients ranged from 11 to 34 years, i.e. within the reported age range. The majority of the cases in our cohort had typical clinical, radiological and pathological features of chondroblastoma. These cases involved the epiphysis or apophysis of long bones, metatarsals, scapula, and ischium. None of our cases involved the carpal bones. Most of the tumours presented as well-circumscribed lesions within the bone, and cortical breakthrough was very uncommon.
Behjati et al. screened 77 chondroblastomas, and found H3 mutations in 95% of the cases. All of the mutations were K36M, with a majority in H3F3B and the rest in H3F3A. 2 The authors also found one of 15 clear cell chondrosarcomas and one of 75 conventional chondrosarcomas harbouring H3K36M mutations. Amary et al. further assessed the value of using immunohistochemistry for H3K36M (mutantspecific antibody), and found that immunoexpression is highly specific for K36M mutation status, and is a valuable diagnostic tool for chondroblastoma. 8 Our results confirmed the presence of H3K36M in the vast majority of chondroblastomas with typical morphology, and showed that immunoreactivity of H3K36M antibody is highly sensitive for chondroblastoma.
A few recent studies have examined the underlying mechanisms of tumorigenesis induced by the H3K36M mutation. 3, 9 One postulated mechanism is reprogramming of the epigenome of chondrocytes by altering histone methylation, especially reducing H3K36 methylation. 9 Lu et al. found that the oncogenic H3K36M mutation is associated with H3K36 hypomethylation and H3K27 hypermethylation. 3 In the interplay of histone modifications, H3K27 methylation is increased in the absence of H3K36 methylation. 10 In our current study, we examined histone methylation status by using immunohistochemistry with antibodies against H3K36me3 and H3K27me3. All H3K36M-immunoreactive chondroblastomas showed heterogeneous expression (on a scale of 1+ to 3+) of H3K27me3 and H3K36me3. No complete loss of H3K36me3 methylation was observed. Similar to our study, Cleven et al. found a mosaic type (defined as <50% of nuclei) in six of 10 chondroblastoma samples. 11 We had only one case of chondroblastoma that was negative for H3K36M immunostaining, and we did not have enough material to assess the effect of H3K36M mutation on histone methylation in that case. Interestingly, when we performed semiquantitative analysis using the modified H-score and correlated the methylation patterns of H3K27me3 and H3K36me3, we found a positive correlation. A similar correlation study was not performed in the study of Lu et al., and our finding of a positive correlation should not be interpreted as being contradictory to their findings of hypomethylation of H3K36 and hypermethylation of H3K27 associated with H3K36M transgenes. 3 Whether this represents an aberrant methylation pattern is yet to be determined, and additional studies are needed to clarify this.
Our study showed that SATB2 is positive in the majority of chondroblastomas. SATB2 is a transcription factor that plays an important role in osteoblast differentiation and bone formation. 12 The use of SATB2 immunohistochemistry as a marker of osteoblastic differentiation was shown by Conner et al., who demonstrated frequent nuclear staining of SATB2 in osteosarcoma and other bone-forming tumours. 13 Non-specific staining, usually weak and focal, is seen in chondromyxoid fibroma, unclassified pleomorphic sarcomas, fibrosarcoma, monophasic synovial sarcoma, and rare sclerosing epithelioid fibrosarcoma. 14, 15 Chondroblastoma is classified as a chondrogenic tumour in the current World Health Organization classification. 16 Previous immunohistochemical studies have shown that the tumour cells of chondroblastoma express SOX9, 17 S100, and proteoglycan, 18 supporting the chondrogenic nature of this tumour. However, chondroblastomas can produce osteoid, 19 and lack collagen type II expression and isocitrate dehydrogenase mutation. 17, 20 In this respect, it is not surprising that SATB2 is positive in some cases. From a practical point of view, SATB2 positivity should not be used as evidence to exclude the diagnosis of chondroblastoma.
Chondroblastomas very rarely metastasise. In our cohort of 27 cases, one case developed lung metastasis. Lin et al. studied 82 consecutive cases of chondroblastoma, and identified three cases who had local recurrences and then distant metastases. 21 In the majority of the reported larger series of chondroblastomas (up to 103 cases), metastases were seen in only one to two cases, and always presented in the lungs. [22] [23] [24] There are limited follow-up data on metastatic chondroblastoma in the literature. The case reported by Sohn et al. was followed for 3 years with no recurrence or new metastasis. 23 Although metastases tend to behave in a benign fashion, malignant transformation was seen in rare instances. Viswanathan et al. reported one case of malignant transformation after three local recurrences. 24 In the three cases of metastatic chondroblastoma reported by Lin et al., the tumours underwent local recurrence followed by malignant transformation and metastases. 21 In summary, our study has confirmed that immunostaining of H3K36M is a useful ancillary study with which to establish a diagnosis of chondroblastoma. H3K27me3 and H3K36me3 antibodies show heterogeneous expression, making it difficult to evaluate the alterations of histone methylation in H3K36M-mutated cases by immunohistochemical analysis. One should be aware that the majority of chondroblastomas express SATB2 on immunohistochemical analysis.
